‘Breakthrough therapy’: a new Chinese drug shows record treatment success against one of the deadliest lung cancers

Source: China – South China Morning PostPhase 2 clinical trial of sunvozertinib shows 61 per cent anti-tumour activity response, higher than any previous candidates, according to paper in The Lancet Respiratory Medicine.Read More